Year 2023 / Volume 115 / Number 8
Original
Delays to surgery following chemoradiotherapy lead to poorer oncologic outcomes in patients with localized pancreatic adenocarcinoma

428-434

DOI: 10.17235/reed.2022.9256/2022

Javier A. Cienfuegos, Pablo Martí-Cruchaga, Gabriel Zozaya, José Luis Hernández Lizoain, Fernando Martínez Regueira, Fernando Pardo, Javier Rodríguez, Leire Arbea Moreno, Fernando Rotellar,

Abstract
Background: although neoadjuvant chemoradiotherapy (NCRT) and surgery are accepted as treatments for pancreatic ductal adenocarcinoma (PDAC), some authors have highlighted the risks of delaying surgery. The objective of this study was to analyze the impact of prolonging the time interval between NCRT and surgery (NCRT-TTS) in PDAC. Methods: patients treated with NCRT and pancreatoduodenectomy (PD) were identified. Clinical, histopathological variables were analyzed about whether NCRT-TTS was greater or less than 50 days. Five- and ten-year overall survival (OS) and disease-free survival (DFS) were analyzed depending on whether the delay was greater than 50 days or not. Results: one hundred (8.3 %) of 120 eligible patients underwent PD (61 male, median age of 63.7 years). In 71 (71 %) patients, the median NCRT-TTS was 39 (24-50) days and in 29 (29 %) 61 days. There were no differences between the two groups except for carbohydrate antigen 19-9 (CA 19-9) levels, the incidence of cholangitis, American Society of Anesthesiologists (ASA) score, intraoperative blood transfusions and degree of histopathologic response (all p < 0.001). Median DFS when the NCRT-TTS was less than 50 days was higher than when the interval exceeded 50 days (51.0 months [95 % CI: 20.3-81.6] vs 17.0 months [95 %: CI 10.9-23.0]; HR [95 % CI 1.08-3.46], p = 0.026). Five-year DFS was higher in the subgroup with NCRT-TTS of less than 50 days compared to the group with an interval of more than 50 days (43.5 % vs 23.65 % [HR 1.812, 95 % CI: 1.001-3.280], p = 0.050). Conclusions: an increase in the NCRT-TTS > 50 days is associated with poorer OS and DFS in patients with localized PDAC treated with NCRT and PD.
Share Button
New comment
Comments
No comments for this article
References
1. Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. JAMA 2021;326:851–862. Available at: http://www.ncbi.nlm.nih.gov/pubmed/34547082.
2. Patel SH, Katz MHG, Ahmad SA. The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Annals of Surgical Oncology 2021;28:4104–4129.
3. Gemenetzis G, Groot VP, Yu J, et al. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. Annals of surgery 2018;268:408–420.
4. Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020; 38: 1763–1773.
5. Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nature Reviews Clinical Oncology 2019;16:11–26.
6. Belfiori G, Crippa S, Francesca A, et al. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Annals of surgical oncology 2021;28:8249–8260. Available at: http://www.ncbi.nlm.nih.gov/pubmed/34258720.
7. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, Version 2.2021. JNCCN Journal of the National Comprehensive Cancer Network 2021;19:439–457.
8. Evans DB, Tolat PP, Christians KK. Pancreaticoduodenectomy and total pancreatectomy for cancer. In: Fischer JL, editor. Fischer’s Mastery of Surgery, Seventh Edition.Vol 2. 7th ed. Philadelphia: Wolters Kluwer/Lippinct Willimas&Wilkins, 2018:1552–1572.
9. Keats AS. The ASA classification of physical status--a recapitulation. Anesthesiology 1978;49:233–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/697075.
10. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004;240:205–213.
11. Washington K, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with carcinoma of the pancreas. In: College of American of Pathologist, editor. Cancer Protocol Templates., 2016. Available at: https://documents.cap.org/protocols)cp-pancreas.
12. Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47:141–146.
13. Batsakis JG. Nerves and neurotropic carcinomas. The Annals of Otology, Rhinology, and Laryngology 1985;94:426–427.
14. Chatterjee D, Rashid A, Wang H, et al. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. American Journal of Surgical Pathology 2012;36:552–559.
15. Kakar S, Pawlik TM, Allen PJ, Vauthey JN. Exocrine pancreas. In: American Joint Committee on Cancer., editor. AJCC cancer staging manual. 8th ed. Chicago: Springer, 2017:337–347.
16. Tzeng C-WD, Fleming JB, Lee JE, et al. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB : the official journal of the International Hepato Pancreato Biliary Association 2012;14:365–72. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22568412.
17. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology 2008;26:3496–3502.
18. Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013;119:2692–2700.
19. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. Annals of Surgical Oncology 2001;8:123–132.
20. Deidda S, Elmore U, Rosati R, et al. Association of Delayed Surgery with Oncologic Long-term Outcomes in Patients with Locally Advanced Rectal Cancer Not Responding to Preoperative Chemoradiation. JAMA Surgery 2021;156:1141–1149.
21. Azab B, Macedo FI, Chang D, et al. The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients. Clinical Medicine Insights Oncology 2020;14:1179554920919402. Available at: http://www.ncbi.nlm.nih.gov/pubmed/32669884..
22. Cloyd JM, Katz MHG, Prakash L, et al. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Journal of Gastrointestinal Surgery 2017;21:164–174.
23. Kubo H, Ohgi K, Sugiura T, et al. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion. Annals of surgical oncology 2022. Available at: http://www.ncbi.nlm.nih.gov/pubmed/35368218.
24. Yamada M, Sugiura T, Okamura Y, et al. Microscopic Venous Invasion in Pancreatic Cancer. Annals of Surgical Oncology 2018;25:1043–1051.
Related articles

Editorial

Fewer endoscopists should perform more ERCPs

DOI: 10.17235/reed.2023.9507/2022

Citation tools
Cienfuegos J, Martí-Cruchaga P, Zozaya G, Hernández Lizoain J, Martínez Regueira F, Pardo F, et all. Delays to surgery following chemoradiotherapy lead to poorer oncologic outcomes in patients with localized pancreatic adenocarcinoma. 9256/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1171 visits.
This article has been downloaded 96 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 04/10/2022

Accepted: 08/11/2022

Online First: 22/11/2022

Published: 26/07/2023

Article Online First time: 49 days

Article editing time: 295 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology